Franklin Resources Inc. Decreases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Franklin Resources Inc. lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 24.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 184,027 shares of the company’s stock after selling 59,733 shares during the quarter. Franklin Resources Inc.’s holdings in Krystal Biotech were worth $28,830,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of KRYS. Alliancebernstein L.P. grew its holdings in Krystal Biotech by 4.7% in the fourth quarter. Alliancebernstein L.P. now owns 31,120 shares of the company’s stock worth $4,875,000 after purchasing an additional 1,400 shares during the last quarter. Pier 88 Investment Partners LLC boosted its position in shares of Krystal Biotech by 6.2% in the 4th quarter. Pier 88 Investment Partners LLC now owns 3,750 shares of the company’s stock worth $587,000 after purchasing an additional 220 shares in the last quarter. Norges Bank purchased a new position in Krystal Biotech during the 4th quarter worth $34,391,000. Blair William & Co. IL grew its stake in Krystal Biotech by 33.7% during the 4th quarter. Blair William & Co. IL now owns 7,443 shares of the company’s stock worth $1,166,000 after buying an additional 1,875 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Krystal Biotech by 18.7% during the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company’s stock valued at $23,786,000 after buying an additional 23,934 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $171.30 on Friday. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The company has a market capitalization of $4.93 billion, a PE ratio of 57.29 and a beta of 0.75. The company has a fifty day moving average of $173.27 and a 200 day moving average of $173.07.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 EPS. Research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target for the company. Citigroup boosted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).